Colleran David, EVP, General Counsel, and Corporate Secretary, has demonstrated a consistent pattern of selling activity in Anika Therapeutics (ANIK) shares, with no recorded purchases across 23 transactions totaling $335,633.67 in sales. The transactions, spanning from March 2024 to March 2026, were executed primarily under code "F" (indicating open-market or privately negotiated sales), with the largest single sale occurring on March 14, 2026, valued at $59,185.60. Earlier sales included a $58,027.50 transaction on March 11, 2024, followed by additional disposals of $40,799.10 and $27,479.02 the same day.
The absence of any buy transactions suggests a one-directional reduction in holdings over the observed period. Notably, the sales were spaced across multiple dates rather than concentrated in a single event, with no recent activity reported beyond March 2026. While the filings do not specify the reasons for the disposals, the data reflects a steady divestment in ANIK shares over a two-year window, with no offsetting acquisitions. The transactions were all tied to ANIK, indicating no diversification into other securities during this period.
AI-assisted summary